Shanghai Securities News and cnstock news   Joincare announced on the evening of April 9 that the Compound Ipratropium Bromide Solution for Inhalation developed by it has recently received the Drug Registration Approval issued by the State Drug Administration.

The drug is administered by a combination of ipratropium bromide and salbutamol sulfate to simultaneously act on the muscarinic and β2-adrenergic receptors in the lungs and relax the respiratory smooth muscle from main trachea to terminal bronchioles. It is suitable for patients requiring a combination of bronchodilators to treat reversible bronchospasm associated with airway obstructive diseases with a curative effect superior to administration of a single drug. It is a clinical drug for patients with moderate to severe asthma and COPD.

According to the announcement, as of the date, the direct research and development expenses of the drug were about 6,238,400 yuan.

According to the announcement, the Compound Ipratropium Bromide Solution for Inhalation currently available in China is only Boehringer Ingelheim’s “Keite®”. According to IQVIA data, the domestic sales of the product in 2018 were about 343.44 million yuan.

According to the SFDA CDE website and the Xianda database, as of the date of announcement, only the company has obtained the registration approval for this variety except for original patented products. Another company has submitted an application for registration of this variety, which is currently under review and approval. (Huang Shu)

Reprinted from: cnstock